Our aim is to develop a simple and effective method for the delivery of tetanus vaccines by non-invasive application of expression vectors onto the skin. The hypothesis is that the expression of tetanus toxin C-fragment in the outer layer of skin can induce systemic immune responses against the toxin. We have demonstrated that animals could be vaccinated by non-invasive application of expression vectors encoding specific antigens onto the skin. These studies will further develop skin-targeted non-invasive vaccines, and specifically determine whether this novel approach for the delivery of vaccines can mobilize the immune repertoire toward a beneficial immune protection against tetanus. In this project, non-invasive vaccination onto the skin (NIVS) against tetanus will be developed by formulating DNA/adenovirus and DNA/liposome complexes into skin-targeted non-invasive tetanus vaccines. Efficacy of NIVS will be compared with those induced by other means. The overall goal of these experiments is to determine whether tetanus vaccines can be effectively delivered by non-invasive application of DNA onto the skin that requires a lower level of skill in a needle-free manner.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41AI044520-01
Application #
2777505
Study Section
Special Emphasis Panel (ZRG5-MBC-1 (01))
Program Officer
Klein, David L
Project Start
1999-05-01
Project End
2000-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Vaxin Inc.
Department
Type
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code